Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19

Authors

  • Samuel Theodorus Sutanto Faculty of Medicine, Universitas Kristen Krida Wacana, Jakarta, Indonesia
  • Robert Sinto Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Adeline Pasaribu Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Sharifah Shakinah Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Keywords:

antiviral, COVID-19, molnupiravir, nirmatrelvir/ritonavir, SARS-CoV-2

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, molnupiravir and nirmatrelvir/ritonavir, that have been studied extensively in treating COVID-19 with promising results, and their availability in Indonesia. Molnupiravir and nirmatrelvir/ritonavir are two of many repurposed drugs in clinical trials, which have been reported to have a mechanism in quick clearance of SARS-CoV-2, reduction in viral load, and fast symptoms recovery time in phase 1 and 2 clinical trials. Phase 2/3 clinical study in COVID-19 patients without any indication for hospitalization showed that molnupiravir and nirmatrelvir/ritonavir significantly reduced the risk of hospitalization and death.

References

John Hopkins Univeristy. COVID-19 Dashboard by the Center for Systems and Engineering at Johns Hopkins University. Published 2022. Accessed September 21, 2022. https://www.coronavirus.jhu.edu/map.html

Kementerian Kesehatan Republik Indonesia. Situasi Terkini Perkembangan Coronavirus Disease (COVID-19). Published 2022. Accessed September 21, 2022. https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-08-agustus-2022

Kementerian Kesehatan Republik Indonesia. Vaksinasi COVID-19 Nasional. Published 2022. Accessed September 21, 2022. https://vaksin.kemkes.go.id/#/vaccines

Drozdzal S, Rosik J, Lechowicz K, et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat. 2021;59:1-27. doi:doi.org/10.1016/j.drup.2021.100794

Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother. 2022;146(January). doi:doi.org/10.1016/j.biopha.2021.112517

Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI. An update of anti-viral treatment of COVID-19. Turkish J Med Sci. 2021;51(SI1):3372-3390. doi:10.3906/sag-2106-250

Hung YP, Lee JC, Chiu CW, et al. Oral Nirmatrelvir/Ritonavir therapy for COVID-19: The dawn in the dark? Antibiotics. 2022;11(2):5-11. doi:10.3390/antibiotics11020220

Imran M, Arora MK, Mohammed S, et al. Discovery, development, and patent trends on Molnupiravir: A prospective oral treatment for COVID-19. Molecules. 2021;26:5795.

Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv Prepr Serv Heal Sci. 2021:1-30. doi:10.1101/2021.06.17.21258639

Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):1-11. doi:10.1126/scitranslmed.abl7430

Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022;10(1):1-7. doi:10.1002/prp2.909

Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr Clin Res Rev. 2021;15(6):102329. doi:10.1016/j.dsx.2021.102329

National Institutes of Health. Molnupiravir. NIH. Published 2022. Accessed June 4, 2022. https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/molnupiravir/#:~:text=In nonhospitalized patients aged ≥,(Paxlovid)%2C sotrovimab%2C or

Burhan E, Susanto AD, Nasution SA, et al. Pedoman Tatalaksana COVID-19. PDPI PERKI PAPDI PERDATIN IDAI; 2022.

Thorlund K, Sheldrick K, Meyerowitz-Katz G, Singh S, Hill A. Making statistical sense of the Molnupiravir MOVe-OUT clinical trial. Am J Trop Med Hyg. 2022;106(5):1301-4. doi:10.4269/ajtmh.21-1339

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509-520. doi:10.1056/nejmoa2116044

Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for high-risk, Nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-408. doi:10.1056/nejmoa2118542

McDonald EG, Lee TC. Nirmatrelvir-ritonavir for COVID-19. CMAJ. 2022;194(6):218. doi:10.1503/cmaj.220081

National Institutes of Health. Ritonavir-boosted Nirmatrelvir (Paxlovid). NIH. Published 2022. Accessed June 4, 2022. https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/

Lai CC, Wang YH, Chen KH, Chen CH, Wang CY. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. Viruses. 2022;14(8):1-10. doi:10.3390/v14081706

Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr Clin Res Rev. 2022;16(January):1-10. doi:doi.org/10.1016/j.dsx.2022.102396

Toussi SS, Neutel JM, Navarro J, et al. Pharmacokinetics of oral Nirmatrelvir/Ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment. Clin Pharmacol Ther. 2022;0(0):1-9. doi:10.1002/cpt.2688

POM B. SIARAN PERS Badan POM terbitkan emergency use authorization untuk obat Molnupiravir. Published 2022. Accessed June 2, 2022. https://www.pom.go.id/new/view/more/pers/636/SIARAN-PERS-Badan-POM-Terbitkan-Emergency-Use-Authorization-untuk-Obat-Molnupiravir.html

Kompas.com. Mengenal Molnupiravir dan Paxlovid, obat COVID-19 yang digunakan di Indonesia. Published 2022. Accessed June 2, 2022. https://www.kompas.com/sains/read/2022/01/13/193000823/mengenal-molnupiravir-dan-paxlovid-obat-covid-19-yang-digunakan-di?page=all

Downloads

Published

2023-01-10

How to Cite

Sutanto, S. T., Sinto, R., Pasaribu, A., & Shakinah, S. (2023). Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19. Acta Medica Indonesiana, 54(4), 638. Retrieved from https://actamedindones.org/index.php/ijim/article/view/2115

Issue

Vol. 54 No. 4 (2022): Acta Medica Indonesiana

Section

REVIEW ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.